EICHOR
● Completed
Phase III Study of Lenalidomide and Dexamethasone With or Without Elotuzumab to Treat Relapsed or Refractory Multiple Myeloma
Condition: Lymphoma · Multiple Myeloma · Sponsor: Bristol-Myers Squibb
About this study
The purpose of the study is to determine whether the addition of Elotuzumab to Lenalidomide/low-dose Dexamethasone will increase the progression free survival (PFS).
This description comes directly from the study's public registry record.
Talk to the study team
No contact information is available for this study as per the public registry record.
Always discuss trial participation with your own doctor first.
Locations (216)
| Northwest Alabama Cancer Center, Pc | Muscle Shoals, Alabama, United States | — |
| Acrc/Arizona Clinical Research Center, Inc. | Tucson, Arizona, United States | — |
| Local Institution | Berkeley, California, United States | — |
| Local Institution | Burbank, California, United States | — |
| Compassionate Cancer Res Grp | Corona, California, United States | — |
| Local Institution | Corona, California, United States | — |
| San Diego Pacific Oncology& Hematology Associates, Inc | Encinitas, California, United States | — |
| Local Institution | Greenbrae, California, United States | — |
| Ucla-Division Of Hematology/Oncology | Los Angeles, California, United States | — |
| Medical Oncology Care Associates | Orange, California, United States | — |
| Sharp Clinical Oncology Research | San Diego, California, United States | — |
| Local Institution | Vallejo, California, United States | — |
+ 204 more locations — full list on the registry record.
Follow this study
Save your interest here for when the public record changes — results posted, or the study's status changes. Email alerts for this study aren't switched on yet.
We keep this only about this public record, and never email you without alerts being switched on. Want it removed at any time? Email hello@eichor.com. Never medical advice. By subscribing you agree to our Terms of Use and Privacy Policy.
This page is independently generated by Eichor from the public ClinicalTrials.gov record and re-synced daily. It is not the sponsor's official website unless claimed. Nothing here is medical advice; eligibility is always determined by the study team — talk to your own doctor first.
Source record: clinicaltrials.gov/study/NCT01239797